Cambridge, United States
Syros Pharmaceuticals, founded in 2012, is a trailblazer in the Biotechnology and Pharmaceutical industries, known for its mission: "By redefining the power of small molecules to control gene expression, we aim to provide a profound benefit for patients". Headquartered in the United States, Syros is focusing on developing leading treatments for hematologic malignancies. A key innovation is tamibarotene, an oral selective RARα agonist, targeted at frontline patients with higher-risk myelodysplastic syndrome and RARA gene overexpression.
Recent financial momentum is highlighted by a substantial $45.00M post-IPO equity investment secured on 01 December 2023, showcasing confidence from eminent investors such as Flagship Pioneering, Invus, Adage Capital Management, Blue Owl Capital, Deep Track Capital, Samsara BioCapital, DAFNA Capital Management, LLC, and Bain Capital Life Sciences.
Syros stands strategically positioned to transform care standards for blood disorders, indicating a promising trajectory for long-term growth and clinical impact.
Oxilight
MedBrain Global